← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Visionary Pharmaceuticals, Inc.
San Diego, CA
$2,711,481
Total funding
5
Grants
Funding over time
peak $824.7K · FY2013–21$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,711,481 · 5
By mechanism
R44$1,492,636 · 1
R43$1,218,845 · 4
Investigators at Visionary Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2$824,726
R44 · FY2014 · DK
The Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD- Phase 2$667,910
R44 · FY2015 · DK
Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer$300,000
R43 · FY2019 · CA
Development of dual inhibitors of the kinases SGK1 and AKT1 for blockade of a critical pathway in triple-negative breast cancer$299,982
R43 · FY2019 · CA
Development of RORgt Immunomodulators Targeting the TH17 Axis in IBD$232,616
R43 · FY2013 · DK
Identification of RORg drug candidates for the treatment of NASH$156,503
R43 · FY2017 · DK
Identification of RORg drug candidates for the treatment of NASH$143,482
R43 · FY2016 · DK
Development of inhibitors of the SGK1 kinase, a critical target in anaplastic thyroid cancer$86,262
R43 · FY2021 · CA